4.3 Article

Characteristics and risk factors of pulmonary arterial hypertension in patients with primary Sjogren's syndrome

期刊

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
卷 21, 期 5, 页码 1068-1075

出版社

WILEY
DOI: 10.1111/1756-185X.13290

关键词

clinical characteristics; primary Sjogren's syndrome; pulmonary arterial hypertension; risk factors

资金

  1. Chinese National Key Research RD Program [2017YFC0907601, 2017YFC0907605]

向作者/读者索取更多资源

AimTo describe baseline characteristics of patients with primary Sjogren's syndrome (pSS) with right heart catheterization (RHC)-confirmed pulmonary arterial hypertension (PAH) and explore risk factors for PAH in pSS. MethodsThis case-control study included consecutive patients hospitalized with pSS-PAH from 2007 to 2015, and pSS patients without PAH (in a 4 : 1 ratio) as controls. All patients fulfilled the 2002 American-European Consensus Group classification criteria for pSS-PAH was defined according to RHC-based European Society of Cardiology/European Respiratory Society guidelines. Associated variables were analyzed by univariate binary logistic regression to identify possible risk factors for PAH. ResultsTwenty-nine patients with RHC-confirmed pSS-PAH were included (mean age at onset, 38.4 8.3 years; mean pSS duration, 54.6 months). PAH was the initial manifestation of pSS in 12 patients (41.4%), and shortness of breath was the most common symptom (29/29, 100%). Mean pulmonary arterial pressure was 51.8 +/- 10.0 mmHg, mean cardiac index was 2.3 +/- 0.8 L/min/m(2), and mean pulmonary vascular resistance was 13.0 +/- 6.0 Wood units in this group. Treatments included immunosuppressive agents (93.1%) and PAH-targeted therapies (86.2%). We identified four independent risk factors for PAH in pSS: Raynaud's phenomenon (odds ratio [OR] = 9.660, P = 0.000), rheumatoid factor 200 U/mL (OR = 6.691, P = 0.001), hepatic injury (OR = 3.284, P = 0.008) and pericardial effusion (OR = 3.279, P = 0.016). ConclusionsPAH can be the first manifestation of pSS. The pSS patients with Raynaud's phenomenon, high-titer rheumatoid factor, hepatic injury or pericardial effusion should be screened for PAH.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据